Melanoma Coverage from Every Angle
Advertisement
Advertisement

Does Immunotherapy Offer Survival Advantage in Resected Cutaneous Melanoma?

By: Cordi Craig
Posted: Monday, March 16, 2020

The phase III E1609 trial, published in the Journal of Clinical Oncology, found that patients with resected cutaneous melanoma who were treated with adjuvant ipilimumab at 3 mg/kg seemed to achieve better overall survival outcomes than patients treated with the active control regimen, high-dose interferon alfa-2b. Ahmad A. Tarhini, MD, PhD, of the H. Lee Moffitt Comprehensive Cancer Center, Tampa, Florida, and colleagues also reported that, although ipilimumab at 10 mg/kg is the approved adjuvant therapy dosage, patients experienced greater toxicity and inferior efficacy than high-dose interferon alfa-2b.

The research team randomly assigned 1,670 adults with resected cutaneous melanoma to receive ipilimumab at 3 mg/kg (n = 523), ipilimumab at 10 mg/kg (n = 511), or high-dose interferon alfa-2b (n = 636). Using a two-step hierarchical approach, the researchers first evaluated ipilimumab at 3 mg/kg versus high-dose interferon alfa-2b and then ipilimumab at 10 mg/kg versus high-dose interferon alfa-2b.

Grade 3 or higher treatment-related adverse events were reported in 37% of patients in the low-dose ipilimumab arm, 79% in the interferon arm, and 58% in the high-dose ipilimumab arm. Adverse events led to treatment discontinuation in 35%, 20%, and 54% of patients, respectively. An intent-to-treat analysis of ipilimumab at 3 mg/kg versus interferon significantly favored ipilimumab (P = .044). In cases with disease progression, there were significantly higher rates of salvage ipilimumab use after high-dose interferon alfa-2b than low-dose or high-dose ipilimumab (P < .001). Additionally, there was a substantial amount of treatment crossover from interferon to low-dose ipilimumab, suggesting the team’s results of the benefits of ipilimumab at 3 mg/kg may have been conservative.

In the second step of the analysis, no significant survival trends favored the use of ipilimumab at 10 mg/kg. The researchers speculated that increased toxicities in patients treated with higher-dose ipilimumab may have affected outcomes.

Disclosure: For full disclosures of the study authors, visit ascopubs.org.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.